Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Lisa Dean Moseley Fellowship in Cancer Stem Cell Research

The Cawley Center for Translational Cancer Research (CTCR) at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is seeking applicants for the Lisa Dean Moseley Post-doctoral fellowship in Translational Cancer Stem Cell Research. This program offers training and mentorship to post-doctoral fellows and early career physician scientists in a unique environment encompassing both translational and clinical oncology research.

The awardees will be hosted within established research labs in the Cawley CTCR and will be embedded into multi-disciplinary teams comprised of scientists, clinicians and patient advocates. Fellows will be offered a one-year stipend plus benefits with an optional second year dependent upon performance. Applicants should be within one year of completion of a Ph.D. in biological sciences, immunology, cancer research or a related field, or a post-graduate resident within 1-3 years of completion of a medical degree.

Applicants should send the following to CTCR@Christianacare.org: Cover letter, Curriculum Vitae, including full publication list, names and contact information (email and phone number) of 2-3 references (including Ph.D. or residency supervisor). 

The Lisa Dean Moseley Fellowship in Cancer Stem Cell Research is made possible through funding generously provided by the Lisa Dean Moseley Foundation based in Wilmington, Delaware.


About the Cawley Center for Translational Cancer Research

The Cawley Center for Translational Cancer Research (CTCR) brings scientific discoveries from the bench to the bedside of patients. The CTCR encompasses a 7,000 square foot research lab at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute with research programs in several solid tumors. In addition to in-house flow cytometry and primary tissue cores, including a Tissue Procurement Center of over 6,000 specimens, the CTCR has formal research alliances with the University of Delaware and the Wistar Cancer Institute in Philadelphia, allowing access to state-of-the-art core facilities and research support.  


About the Helen F. Graham Cancer Center & Research Institute

The Helen F. Graham Cancer Center & Research Institute, a National Cancer Institute Community Oncology Research Program, is part of ChristianaCare, one of the country’s largest health care systems with 52,339 admissions, 37,634 surgeries, and 195,998 emergency department visits. With more than 248,000 patient visits, the Graham Cancer Center is recognized as a national model for multidisciplinary cancer care and a top enroller in U.S. clinical research trials (29% accrual rate). Annually there are more than 3,200 newly diagnosed cancer patients. Its Cawley Center for Translational Cancer Research, located in the Graham Cancer Center, consists of a Tissue Procurement Center, world-renowned Gene Editing Institute, Statewide High-Risk Family Cancer Registry with eight full-time genetic counselors, and collaborations with acclaimed scientists at The Wistar Cancer Institute in Philadelphia. The Cawley CTCR is opening new avenues to more quickly translate cancer science into cancer medicine. The 240,000 square foot outpatient cancer center has 12 multidisciplinary disease site centers allowing patients to see the three disciplines of surgical, medical and radiation oncology, including subspecialists and support service teams, in one visit.  

Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4500